Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus

Acta Biomaterialia

Volumn 43, Issue , 2016, Pages 61-70

  Henry, Christine E ^b   Wang, Ying Ying ^d   Yang, Qi ^a   Hoang, Thuy ^d   Chattopadhyay, Sumon ^d   Hoen, Timothy ^d   Ensign, Laura M ^d   Nunn, Kenetta L ^b   Schroeder, Holly ^a   McCallen, Justin ^a   Moench, Thomas ^e   Cone, Richard ^d   Roffler, Steve R ^f   Lai, Samuel K ^a,b,c  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b Biomedical Research Imaging Center   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e REPROTECT INC   (United States)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Diffusion; IgG; IgM; Mucosal immunity; Nanomedicine; PEGylation

Indexed keywords

ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; BODY FLUIDS; CONTROLLED DRUG DELIVERY; CROSSLINKING; FUNCTIONAL POLYMERS; MAMMALS; NANOPARTICLES; PLASTIC COATINGS; TARGETED DRUG DELIVERY; VIRUSES;

BIODISTRIBUTIONS; COATED NANOPARTICLES; IGG; IGM; MUCOSAL IMMUNITY; MUCOSAL SURFACE; PEGYLATED; PEGYLATED NANOPARTICLES; PEGYLATION; SYSTEMIC CIRCULATION;

MEDICAL NANOTECHNOLOGY;

ESTRADIOL BENZOATE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MACROGOL; MUCIN; NANOCOATING; NANOPARTICLE; VANCOMYCIN; WATER; ANTIBODY; MACROGOL DERIVATIVE;

ADVECTION; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG DISTRIBUTION; DRUG PENETRATION; EX VIVO STUDY; FEMALE; IMMOBILIZATION; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX MUCUS; VAGINA EPITHELIUM; VAGINA MUCOSA; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DIFFUSION; DRUG EFFECTS; FROZEN SECTION; METABOLISM; MUCUS; TISSUE DISTRIBUTION; UTERINE CERVIX; VAGINA;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CERVIX UTERI; DIFFUSION; FEMALE; FROZEN SECTIONS; MICE; MUCUS; NANOPARTICLES; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; VAGINA;

EID: 84991051769     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2016.07.019     Document Type: Article

References (55)

1. [1] Lai, S.K., Wang, Y.Y., Wirtz, D., Hanes, J., Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 61 (2009), 86–100.
2. [2] Lai, S.K., Wang, Y.Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev., 2009, 158–171.
3. [3] Cu, Y., Saltzman, W.M., Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharm. 6 (2009), 173–181.
4. [4] Lai, S.K., O'Hanlon, D.E., Harrold, S., Man, S.T., Wang, Y.Y., Cone, R., Hanes, J., Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA 104 (2007), 1482–1487.
5. [5] Abdulkarim, M., Agullo, N., Cattoz, B., Griffiths, P., Bernkop-Schnurch, A., Borros, S.G., Gumbleton, M., Nanoparticle diffusion within intestinal mucus: three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles. Eur. J. Pharmaceutics Biopharm., 2015.
6. [6] Macierzanka, A., Rigby, N.M., Corfield, A.P., Wellner, N., Bottger, F., Mills, E.N.C., Mackie, A.R., Adsorption of bile salts to particles allows penetration of intestinal mucus. Soft Matter 7 (2011), 8077–8084.
7. [7] Lai, S.K., Wang, Y.Y., Hida, K., Cone, R., Hanes, J., Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. USA 107 (2010), 598–603.
8. [8] Ensign, L.M., Hoen, T.E., Maisel, K., Cone, R.A., Hanes, J.S., Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. Biomaterials 34 (2013), 6922–6929.
9. [9] Wang, Y.Y., Lai, S.K., Suk, J.S., Pace, A., Cone, R., Hanes, J., Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew. Chem. Int. Ed. 47 (2008), 9726–9729.
10. [10] Yang, M., Yu, T., Wang, Y.Y., Lai, S.K., Zeng, Q., Miao, B., Tang, B.C., Simons, B.W., Ensign, L.M., Liu, G., Chan, K.W., Juang, C.Y., Mert, O., Wood, J., Fu, J., McMahon, M.T., Wu, T.C., Hung, C.F., Hanes, J., Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv. Healthcare Mater. 3 (2014), 1044–1052.
11. [11] Ensign, L.M., Tang, B.C., Wang, Y.Y., Tse, T.A., Hoen, T., Cone, R., Hanes, J., Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Trans. Med., 4, 2012, 138ra79.
12. [12] Suk, J.S., Kim, A.J., Trehan, K., Schneider, C.S., Cebotaru, L., Woodward, O.M., Boylan, N.J., Boyle, M.P., Lai, S.K., Guggino, W.B., Hanes, J., Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J. Controlled Release 178 (2014), 8–17.
13. [13] Allen, T.M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A., Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066 (1991), 29–36.
14. [14] Harris, J.M., Chess, R.B., Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003), 214–221.
15. [15] Klibanov, A.L., Maruyama, K., Torchilin, V.P., Huang, L., Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268 (1990), 235–237.
16. [16] Jokerst, J.V., Lobovkina, T., Zare, R.N., Gambhir, S.S., Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 6 (2011), 715–728.
17. [17] Dams, E.T., Laverman, P., Oyen, W.J., Storm, G., Scherphof, G.L., van Der Meer, J.W., Corstens, F.H., Boerman, O.C., Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 292 (2000), 1071–1079.
18. [18] Ishida, T., Masuda, K., Ichikawa, T., Ichihara, M., Irimura, K., Kiwada, H., Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm. 255 (2003), 167–174.
19. [19] Judge, A., McClintock, K., Phelps, J.R., Maclachlan, I., Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13 (2006), 328–337.
20. [20] Semple, S.C., Harasym, T.O., Clow, K.A., Ansell, S.M., Klimuk, S.K., Hope, M.J., Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 312 (2005), 1020–1026.
21. [21] Wang, X., Ishida, T., Kiwada, H., Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Controlled Release 119 (2007), 236–244.
22. [22] Schellekens, H., Hennink, W.E., Brinks, V., The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 30 (2013), 1729–1734.
23. [23] Armstrong, J.K., Leger, R., Wenby, R.B., Meiselman, H.J., Garratty, G., Fisher, T.C., Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood, 102, 2003, 556.
24. [24] Yang, Q., Lai, S.K., Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (2015), 655–677.
25. [25] Wang, Y.Y., Kannan, A., Nunn, K.L., Murphy, M.A., Subramani, D.B., Moench, T., Cone, R., Lai, S.K., IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections. Mucosal Immunol. 7 (2014), 1036–1044.
26. [26] Olmsted, S.S., Padgett, J.L., Yudin, A.I., Whaley, K.J., Moench, T.R., Cone, R.A., Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 81 (2001), 1930–1937.
27. [27] Chen, A., McKinley, S.A., Wang, S., Shi, F., Mucha, P.J., Forest, M.G., Lai, S.K., Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion. Biophys. J. 106 (2014), 2028–2036.
28. [28] Yang, Q., Jones, S.W., Parker, C.L., Zamboni, W.C., Bear, J.E., Lai, S.K., Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol. Pharm. 11 (2014), 1250–1258.
29. [29] Academia Sinica. < http://www.ibms.sinica.edu.tw/~sroff/anti-PEG/anti-PEG_antibody_order.html>. Accessed February 22, 2016.
30. [30] Su, Y.C., Chen, B.M., Chuang, K.H., Cheng, T.L., Roffler, S.R., Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug. Chem. 21 (2010), 1264–1270.
31. [31] Su, Y.C., Al-Qaisi, T.S., Tung, H.Y., Cheng, T.L., Chuang, K.H., Chen, B.M., Roffler, S.R., Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies. mAbs 6 (2014), 1069–1083.
32. [32] Ehrlich, G.K., Michel, H., Chokshi, H.P., Malick, A.W., Affinity purification and characterization of an anti-PEG IgM. J. Mol. Recogn. JMR 22 (2009), 99–103.
33. [33] Apgar, J., Tseng, Y., Fedorov, E., Herwig, M.B., Almo, S.C., Wirtz, D., Multiple-particle tracking measurements of heterogeneities in solutions of actin filaments and actin bundles. Biophys. J. 79 (2000), 1095–1106.
34. [34] Wang, Y.Y., Nunn, K.L., Harit, D., McKinley, S.A., Lai, S.K., Minimizing biases associated with tracking analysis of submicron particles in heterogeneous biological fluids. J. Controlled Release 220 (2015), 37–43.
35. [35] Dawson, M., Wirtz, D., Hanes, J., Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J. Biol. Chem. 278 (2003), 50393–50401.
36. [36] Suh, J., Dawson, M., Hanes, J., Real-time multiple-particle tracking: applications to drug and gene delivery. Adv. Drug Deliv. Rev. 57 (2005), 63–78.
37. [37] Lai, S.K., O'Hanlon, D.E., Harrold, S., Man, S.T., Wang, Y.Y., Cone, R., Hanes, J., Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA 104 (2007), 1482–1487.
38. [38] Li, Z., Palaniyandi, S., Zeng, R., Tuo, W., Roopenian, D.C., Zhu, X., Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl. Acad. Sci. USA 108 (2011), 4388–4393.
39. [39] Usala, S.J., Usala, F.O., Haciski, R., Holt, J.A., Schumacher, G.F., IgG and IgA content of vaginal fluid during the menstrual cycle. J. Reprod. Med. 34 (1989), 292–294.
40. [40] Ensign, L.M., Henning, A., Schneider, C.S., Maisel, K., Wang, Y.Y., Porosoff, M.D., Cone, R., Hanes, J., Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol. Pharm. 10 (2013), 2176–2182.
41. [41] Roche, A.M., Richard, A.L., Rahkola, J.T., Janoff, E.N., Weiser, J.N., Antibody blocks acquisition of bacterial colonization through agglutination. Mucosal Immunol., 2014.
42. [42] Cone, R.A., Mucus. Ogra, P.L., Mestecky, J., Lamm, M.E., Strober, W., Bienenstock, J., McGhee, J.R., (eds.) Handbook of Mucosal Immunology, third ed., 1999, Academic Press, San Diego, 43–64.
43. [43] Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., Kiwada, H., Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Controlled Release 112 (2006), 15–25.
44. [44] Mima, Y., Hashimoto, Y., Shimizu, T., Kiwada, H., Ishida, T., Anti-PEG IgM Is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein. Mol. Pharm. 12 (2015), 2429–2435.
45. [45] Suzuki, T., Ichihara, M., Hyodo, K., Yamamoto, E., Ishida, T., Kiwada, H., Ishihara, H., Kikuchi, H., Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int. J. Pharm. 436 (2012), 636–643.
46. [46] Suzuki, T., Ichihara, M., Hyodo, K., Yamamoto, E., Ishida, T., Kiwada, H., Kikuchi, H., Ishihara, H., Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin. Int. J. Pharm. 476 (2014), 205–212.
47. [47] Ganson, N.J., Kelly, S.J., Scarlett, E., Sundy, J.S., Hershfield, M.S., Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther., 8, 2006, R12.
48. [48] Sundy, J.S., Ganson, N.J., Kelly, S.J., Scarlett, E.L., Rehrig, C.D., Huang, W., Hershfield, M.S., Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56 (2007), 1021–1028.
49. [49] Conley, M.E., Delacroix, D.L., Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense?. Ann. Intern. Med. 106 (1987), 892–899.
50. [50] Mestecky, J., Russell, M.W., Jackson, S., Brown, T.A., The human IgA system: a reassessment. Clin. Immunol. Immunopathol. 40 (1986), 105–114.
51. [51] Mestecky, J., Russell, M.W., Elson, C.O., Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut 44 (1999), 2–5.
52. [52] Lai, S.K., Wang, Y.Y., Cone, R., Wirtz, D., Hanes, J., Altering mucus rheology to “solidify” human mucus at the nanoscale. PLoS One, 4, 2009, e4294.
53. [53] Hashimoto, Y., Shimizu, T., Abu Lila, A.S., Ishida, T., Kiwada, H., Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice. Biol. Pharm. Bull. 38 (2015), 417–424.
54. [54] Wang, Y.Y., Kannan, A., Nunn, K.L., Murphy, M.A., Subramani, D.B., Moench, T., Cone, R., Lai, S.K., IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections. Mucosal Immunol., 2014.
55. [55] Saltzman, W.M., Radomsky, M.L., Whaley, K.J., Cone, R.A., Antibody diffusion in human cervical mucus. Biophys. J. 66 (1994), 508–515.